Compare NABL & MPLT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NABL | MPLT |
|---|---|---|
| Founded | 2000 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 819.9M | 811.3M |
| IPO Year | 2021 | N/A |
| Metric | NABL | MPLT |
|---|---|---|
| Price | $4.96 | $17.89 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 4 |
| Target Price | $8.31 | ★ $31.00 |
| AVG Volume (30 Days) | ★ 2.0M | 123.3K |
| Earning Date | 05-21-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $511,430,000.00 | N/A |
| Revenue This Year | $10.97 | N/A |
| Revenue Next Year | $8.49 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 9.71 | N/A |
| 52 Week Low | $4.15 | $12.24 |
| 52 Week High | $9.04 | $21.55 |
| Indicator | NABL | MPLT |
|---|---|---|
| Relative Strength Index (RSI) | 45.82 | 48.19 |
| Support Level | $4.15 | $16.17 |
| Resistance Level | $5.03 | $20.20 |
| Average True Range (ATR) | 0.22 | 1.32 |
| MACD | 0.09 | 0.03 |
| Stochastic Oscillator | 88.33 | 29.47 |
N-able Inc is a provider of cloud-based software solutions for managed service providers (MSPs), enabling them to support digital transformation and growth for small and medium-sized enterprises. With a flexible technology platform and powerful integrations, N-able makes it easy for MSPs to monitor, manage, and protect their end-customer systems, data, and networks. The company's growing portfolio of management, security, automation, and data protection solutions is built for IT services management professionals. Geographically, the majority of revenue is from the United States. The company also has a presence in the United Kingdom and all other International regions.
MapLight Therapeutics Inc is a biopharmaceutical company. The company is focused on improving the lives of patients suffering from debilitating central nervous system, or CNS, disorders. The company is engaged in psychiatry and neuroscience research to address the lack of circuit-specific pharmacotherapies available for patients. The product candidates of the company include ML-007C-MA, ML-004, ML-021, ML-009, and other pipeline products.